EA202191075A1 - Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний - Google Patents
Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеванийInfo
- Publication number
- EA202191075A1 EA202191075A1 EA202191075A EA202191075A EA202191075A1 EA 202191075 A1 EA202191075 A1 EA 202191075A1 EA 202191075 A EA202191075 A EA 202191075A EA 202191075 A EA202191075 A EA 202191075A EA 202191075 A1 EA202191075 A1 EA 202191075A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- group
- difluoromethoxy
- trifluoromethyl
- methoxy
- chlorine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/235,429 US10807973B2 (en) | 2018-12-28 | 2018-12-28 | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| PCT/US2019/068768 WO2020140050A1 (fr) | 2018-12-28 | 2019-12-27 | Dérivés de n-(4-(oxazol-5-yl) phényl)chromane-3-carboxamide et composés apparentés en tant que stimulateurs de la production de cellules précurseurs rétiniennes pour le traitement de maladies neurorétiniennes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191075A1 true EA202191075A1 (ru) | 2021-10-06 |
Family
ID=69191293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191075A EA202191075A1 (ru) | 2018-12-28 | 2019-12-27 | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10807973B2 (fr) |
| EP (1) | EP3902798B1 (fr) |
| JP (1) | JP7492964B2 (fr) |
| KR (1) | KR20210110652A (fr) |
| CN (1) | CN113227086A (fr) |
| AU (1) | AU2019413682B2 (fr) |
| BR (1) | BR112021011633A2 (fr) |
| CA (1) | CA3125327A1 (fr) |
| CL (1) | CL2021001698A1 (fr) |
| EA (1) | EA202191075A1 (fr) |
| ES (1) | ES2974562T3 (fr) |
| IL (1) | IL284302A (fr) |
| MX (1) | MX2021007815A (fr) |
| PH (1) | PH12021551133A1 (fr) |
| SG (1) | SG11202105229TA (fr) |
| WO (1) | WO2020140050A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10807973B2 (en) * | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| JP2023537814A (ja) * | 2020-06-19 | 2023-09-06 | エンドジーナ セラペウティクス インコーポレーテッド | 網膜色素上皮に関与する疾患の治療及び／又は予防における治療活性物質としての新規化合物及びそれらの使用 |
| US11541039B2 (en) | 2020-10-08 | 2023-01-03 | Endogena Therapeutics, Inc. | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216439A1 (fr) | 1996-09-25 | 1998-03-25 | Derek Van Der Kooy | Produits pharmaceutiques contenant des cellules souches retiniennes |
| EP1101759A4 (fr) | 1998-07-31 | 2001-12-12 | Nippon Soda Co | Composes phenylazole, procede de production desdits composes et medicaments pour le traitement de l'hyperlipidemie |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| WO2009027392A1 (fr) * | 2007-08-27 | 2009-03-05 | Abbott Gmbh & Co. Kg | Composés 4-(4-pyrimidyl)-benzamides et utilisation de ceux-ci comme modulateurs de l'activité de kinases rho (rock) |
| CN101896461A (zh) * | 2007-12-13 | 2010-11-24 | 安姆根有限公司 | γ分泌酶调节剂 |
| CA2709918A1 (fr) | 2007-12-21 | 2009-06-25 | The Scripps Research Institute | Benzopyranes et analogues utilises comme inhibiteurs de la rho kinase |
| US9018202B2 (en) * | 2010-12-03 | 2015-04-28 | Allergan, Inc. | Methods for treating diseases of the retina |
| US20130046003A1 (en) | 2011-07-22 | 2013-02-21 | Mohammed I. Dibas | Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases |
| WO2014079850A1 (fr) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Dérivés hétérocycliques substitués |
| DE102013110714A1 (de) | 2013-09-27 | 2015-04-02 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung |
| US9617214B2 (en) * | 2013-11-08 | 2017-04-11 | The Translational Genomics Research Institute | Compounds for cognitive enhancement and methods of use thereof |
| CA2967327C (fr) | 2014-11-07 | 2020-04-28 | The Johns Hopkins University | Traitement de retinite pigmentaire avec un n-acetylcysteine amide |
| AU2016271152A1 (en) | 2015-05-29 | 2017-12-07 | Edge Therapeutics, Inc. | Compositions and methods for reducing visual loss |
| US10807973B2 (en) * | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
-
2018
- 2018-12-28 US US16/235,429 patent/US10807973B2/en active Active
-
2019
- 2019-12-27 ES ES19842725T patent/ES2974562T3/es active Active
- 2019-12-27 JP JP2021537222A patent/JP7492964B2/ja active Active
- 2019-12-27 US US17/418,019 patent/US20220089583A1/en active Pending
- 2019-12-27 EA EA202191075A patent/EA202191075A1/ru unknown
- 2019-12-27 KR KR1020217023910A patent/KR20210110652A/ko unknown
- 2019-12-27 MX MX2021007815A patent/MX2021007815A/es unknown
- 2019-12-27 AU AU2019413682A patent/AU2019413682B2/en active Active
- 2019-12-27 EP EP19842725.4A patent/EP3902798B1/fr active Active
- 2019-12-27 CA CA3125327A patent/CA3125327A1/fr active Pending
- 2019-12-27 BR BR112021011633-8A patent/BR112021011633A2/pt unknown
- 2019-12-27 SG SG11202105229TA patent/SG11202105229TA/en unknown
- 2019-12-27 CN CN201980085766.5A patent/CN113227086A/zh active Pending
- 2019-12-27 WO PCT/US2019/068768 patent/WO2020140050A1/fr unknown
-
2021
- 2021-05-18 PH PH12021551133A patent/PH12021551133A1/en unknown
- 2021-06-22 IL IL284302A patent/IL284302A/en unknown
- 2021-06-24 CL CL2021001698A patent/CL2021001698A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019413682B2 (en) | 2023-11-23 |
| AU2019413682A1 (en) | 2021-06-03 |
| BR112021011633A2 (pt) | 2021-09-08 |
| CL2021001698A1 (es) | 2021-12-17 |
| IL284302A (en) | 2021-08-31 |
| ES2974562T3 (es) | 2024-06-27 |
| EP3902798C0 (fr) | 2023-12-20 |
| US20200207749A1 (en) | 2020-07-02 |
| CA3125327A1 (fr) | 2020-07-02 |
| CN113227086A (zh) | 2021-08-06 |
| US20220089583A1 (en) | 2022-03-24 |
| MX2021007815A (es) | 2021-10-01 |
| US10807973B2 (en) | 2020-10-20 |
| EP3902798B1 (fr) | 2023-12-20 |
| KR20210110652A (ko) | 2021-09-08 |
| WO2020140050A1 (fr) | 2020-07-02 |
| EP3902798A1 (fr) | 2021-11-03 |
| JP7492964B2 (ja) | 2024-05-30 |
| SG11202105229TA (en) | 2021-07-29 |
| PH12021551133A1 (en) | 2022-02-21 |
| JP2022516087A (ja) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202191075A1 (ru) | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний | |
| AU2015231234B2 (en) | Antifungal compound process | |
| JP2016518437A5 (fr) | ||
| RU2006112428A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2006112427A (ru) | Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| EA002763B1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
| JP2005506308A5 (fr) | ||
| ATE538784T1 (de) | Verfahren zur behandlung von substanzbedingten erkrankungen | |
| CA2962922A1 (fr) | Modulateurs du recepteur de la sphingosine -1-phosphate pour le traitement de troubles cardio-pulmonaires | |
| JP2013522368A5 (fr) | ||
| JP2015502371A5 (fr) | ||
| MA27605A1 (fr) | Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel | |
| JP2004527492A5 (fr) | ||
| EA009193B1 (ru) | N-арилсульфонил-3-аминоалкоксииндолы | |
| PL90030B1 (fr) | ||
| RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
| RU2003128984A (ru) | Производные карбаматов для использования для лечения боли | |
| ATE378046T1 (de) | Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen | |
| JP2005538974A5 (fr) | ||
| EA200700871A1 (ru) | Способы нейропротекции | |
| RU2004103079A (ru) | Новые иммуномодулирующие соединения | |
| EA200300042A1 (ru) | Карбаматные соединения для использования при предотвращении или лечении невропатической боли и гистаминовой головной боли и головной боли, связанной с мигренью |